74 related articles for article (PubMed ID: 15671203)
1. Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
Csajka C; Imbimbo BP; Piccinno A; Dostert P; Verotta D
J Pharmacol Exp Ther; 2005 May; 313(2):647-57. PubMed ID: 15671203
[TBL] [Abstract][Full Text] [Related]
2. CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Mathiesen O; Imbimbo BP; Hilsted KL; Fabbri L; Dahl JB
J Pain; 2006 Aug; 7(8):565-74. PubMed ID: 16885013
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M
Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of CHF3381 in the forebrain.
Barbieri M; Bregola G; Buzzi A; Marino S; Zucchini S; Stables JP; Bergamaschi M; Pietra C; Villetti G; Simonato M
Br J Pharmacol; 2003 Aug; 139(7):1333-41. PubMed ID: 12890713
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
Villetti G; Bergamaschi M; Bassani F; Bolzoni PT; Maiorino M; Pietra C; Rondelli I; Chamiot-Clerc P; Simonato M; Barbieri M
J Pharmacol Exp Ther; 2003 Aug; 306(2):804-14. PubMed ID: 12750440
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.
Zucchini S; Buzzi A; Bergamaschi M; Pietra C; Villetti G; Simonato M
Neuroreport; 2002 Nov; 13(16):2071-4. PubMed ID: 12438928
[TBL] [Abstract][Full Text] [Related]
9. CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
Bassani F; Bergamaschi M; Tonino Bolzoni P; Villetti G
Eur J Pharmacol; 2005 Sep; 519(3):231-6. PubMed ID: 16125167
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for quantification of 3,4-dihydroxyphenylglycol, a norepinephrine metabolite in plasma and brain regions.
Padala NSP; Ajjala DR; Boggavarapu RK; Pantangi HR; Thentu JB; Mohammed AR; Nirogi R
Bioanalysis; 2019 May; 11(10):971-986. PubMed ID: 31218903
[No Abstract] [Full Text] [Related]
12. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
Holford NH; Guentert TW; Dingemanse J; Banken L
Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
[TBL] [Abstract][Full Text] [Related]
13. Norepinephrine metabolism in neuron: dissociation between 3,4-dihydroxyphenylglycol and 3,4-dihydroxymandelic acid pathways.
Dong WX; Ni XL
Acta Pharmacol Sin; 2002 Jan; 23(1):59-65. PubMed ID: 11860739
[TBL] [Abstract][Full Text] [Related]
14. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
Kielbasa W; Lobo E
J Clin Pharmacol; 2015 Dec; 55(12):1422-31. PubMed ID: 26011686
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
Kielbasa W; Pan A; Pereira A
Eur Neuropsychopharmacol; 2015 Mar; 25(3):377-85. PubMed ID: 25637266
[TBL] [Abstract][Full Text] [Related]
18. Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats.
Eisenhofer G; Finberg JP
J Pharmacol Exp Ther; 1994 Mar; 268(3):1242-51. PubMed ID: 8138937
[TBL] [Abstract][Full Text] [Related]
19. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of befloxatone: a brief review.
Rosenzweig P; Patat A; Curet O; Durrieu G; Dubruc C; Zieleniuk I; Legangneux E
J Affect Disord; 1998 Dec; 51(3):305-12. PubMed ID: 10333984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
